Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Goodwin Biotechnology (GBI) and Coldstream have entered into a collaboration for the production and development of high-potency, highly cytotoxic materials.
Subscribe to our email newsletter
GBI will collaborate with Coldstream to perform activities within Coldstream’s cGMP platform of services that include analytical testing, liquid or lyophilized fill and finish, storage and shipment of manufactured highly-potent bioconjugates.
GBI Process Development vice president Muctarr Sesay said that over the last 20 years the company has offered cell culture and purification process development, scale-up, GLP manufacturing and cGMP manufacturing services for cell culture-derived biopharmaceuticals as a contract manufacturing organization (CMO).
"Our GBI scientists will collaborate with Coldstream staff, to develop and manufacture products on behalf of our mutual clients," Sesay added.
Coldstream president and CEO Eric Smart said that Coldstream is also a CMO, tracing its origins to the University of Kentucky’s Center for Pharmaceutical Sciences and Technology, and offers small-volume, parenteral manufacturing services.
"This capability, coupled with the bioconjugation expertise of GBI, will help advance patient care through the delivery of sophisticated potent therapies," Smart added.